文献速递心律失常

达格列净未减少持续性房颤导管消融后早期复发:DARE-AF随机试验

Dapagliflozin to Reduce Early Recurrence After Catheter Ablation for Atrial Fibrillation: The DARE-AF Randomized Clinical Trial.
PubMed 文献 · Circulation · 2025-11-09

DARE-AF为前瞻性开放标签平行随机对照试验,纳入200例无达格列净既定适应证(糖尿病、心衰或慢性肾病)的持续性房颤首次消融患者,1:1随机至达格列净10 mg每日一次术后3个月或对照。3个月房颤负荷两组无显著差异,房性心律失常复发风险亦无差异。

要点

  • 无SGLT2抑制剂适应证的持续性房颤患者,术后3个月达格列净未降低房颤负荷
  • 达格列净组与对照组房性心律失常复发率相近,HR 1.11(95%CI 0.66-1.86)
  • 生活质量与左房内径变化两组均无显著差异

核心结论

  • 在无达格列净既定适应证的持续性房颤患者中,消融术后3个月达格列净治疗未减少心律失常早期复发。

研究设计与样本

  • DARE-AF为前瞻性、开放标签、平行分组随机对照试验,2024年7月至2025年3月纳入200例计划首次导管消融的持续性房颤患者,均无糖尿病、心衰或慢性肾病等达格列净适应证。
  • 患者按1:1随机分配至达格列净组(消融后10 mg每日一次,共3个月)或对照组;主要终点为消融后3个月经7天单导联心电贴评估的房颤负荷。

主要发现

  • 共200例患者随机(平均年龄58.5岁,女性19.5%,持续性房颤≥1年者29.0%),198例纳入主要分析(达格列净组98例,对照组100例)。
  • 消融后3个月房颤负荷两组差异不显著(7.5±23.6% vs 8.1±25.5%;P=0.48)。
  • 房性心律失常复发在达格列净组29例(29.6%)、对照组28例(28.0%),风险比1.11(95%CI 0.66-1.86;P=0.70)。
  • 生活质量变化与左房内径变化均未观察到显著组间差异。

临床怎么用

  • 对于无糖尿病、心衰或慢性肾病等SGLT2抑制剂适应证的持续性房颤患者,不应仅为减少消融术后早期复发而常规使用达格列净。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Observational studies have suggested that SGLT2 (sodium-glucose cotransporter 2) inhibitors are associated with a lower risk of atrial fibrillation (AF) recurrence after catheter ablation in patients with AF with concomitant diabetes, heart failure, or chronic kidney disease. However, no randomized trial to date has tested whether SGLT2 inhibitors reduce AF recurrence after ablation in patients without established indications. We therefore investigated the effect of dapagliflozin on prevention of early recurrence of AF after catheter ablation in patients without current indications for SGLT2 inhibitors. METHODS: The DARE-AF trial (Dapagliflozin on Recurrence After Catheter Ablation for Atrial Fibrillation) was a prospective, open-label, parallel-assignment randomized controlled trial that enrolled 200 patients with persistent AF between July 2024 and March 2025, scheduled to undergo a first catheter ablation procedure and without established indications for dapagliflozin (diabetes, heart failure, or chronic kidney disease). Patients were randomly assigned at a 1:1 ratio to dapagliflozin (10 mg once daily for 3 months after the ablation) or control. The primary end point was AF burden at 3 months after ablation, assessed by 7-day single-lead ECG patches. Secondary outcomes included time to events, quality of life, and improvement of atrial remodeling. RESULTS: A total of 200 patients (mean age 58.5 years, 19.5% women, 29.0% with persistent AF ≥1 year) were randomized, and 198 patients (98 in the dapagliflozin group, 100 in the control group) were included in the primary analysis. Three months after ablation, the difference in AF burden was insignificant between the dapagliflozin group and the control group (7.5±23.6% versus 8.1±25.5%; P=0.48). Atrial arrhythmia recurrence occurred in 29 patients (29.6%) in the dapagliflozin group and 28 patients (28.0%) in the control group (hazard ratio, 1.11 [95% CI, 0.66-1.86]; P=0.70). No significant between-group differences were observed in changes in quality of life or left atrial diameter. CONCLUSIONS: Three-month treatment with dapagliflozin did not reduce the early recurrence of arrhythmia after catheter ablation in patients with persistent AF. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT06433479.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Jiang C, Zhao Z, Yang Z, et al. Dapagliflozin to Reduce Early Recurrence After Catheter Ablation for Atrial Fibrillation: The DARE-AF Randomized Clinical Trial. Circulation. 2025. PMID: 41206792. doi:10.1161/CIRCULATIONAHA.125.077447

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。